Hot Investor Mandate 3: Pharma Firm Invests in Therapeutics in Oncology, Ophthalmology, and Nephrology from Preclinical Onwards

19 May

A fully integrated public biopharmaceutical company with over 20 years’ operation in China’s pharmaceutical industry is interested in equity investments, in-licensing clinical stage assets for development, and will also consider collaborative R&D. Typical equity investments range from $2-3M per deal. The firm has partnered with companies in Japan, the US and Europe, and is currently looking for new opportunities globally with a focus on US and EU.

Currently, the firm is seeking therapeutics in oncology, ophthalmology, and nephrology. The firm is most interested in new formulation and is open to small molecule, biologics, biosimilar, and repurposed drugs. The firm currently focuses on assets in phase 2 clinical trials, but can consider assets from pre-clinical to on-market stages.

The firm is seeking innovative assets that address a large unmet medical need. When making an investment, the firm generally seeks development and/or commercialization rights in China and Southeast Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: